Virulence factors, antibiotic resistance mechanisms and the prevalence of resistance worldwide in Streptococcus pneumoniae

Reviews and Research in Medical Microbiology

Volumn 15, Issue 1, 2004, Pages 27-39

  Dobay, Orsolya ^a,b   Rozgonyi, Ferenc ^b   Amyes, Sebastian G B ^a,c  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Pneumococcus; Resistance mechanisms; Resistance prevalence; Virulence factors

Indexed keywords

ANTIBIOTIC AGENT; AUTOLYSIN; BACTERIAL PROTEIN; BINDING PROTEIN; CEPHALOSPORIN DERIVATIVE; CHEMOKINE; CHLORAMPHENICOL; COMPLEMENT; COTRIMOXAZOLE; CYTOKINE; DEOXYCHOLIC ACID; HYALURONIDASE; KETOLIDE; LIPOTEICHOIC ACID; MACROLIDE; MEMBRANE PROTEIN; N ACETYLMURAMOYLALANINE AMIDASE; PENICILLIN DERIVATIVE; PNEUMOLYSIN; POLYSACCHARIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SIALIDASE; SULFONAMIDE; TEICHOIC ACID; TETRACYCLINE; TRIMETHOPRIM; UNINDEXED DRUG; VANCOMYCIN; VIRULENCE FACTOR;

ANTIBIOTIC RESISTANCE; BACTERIUM ADHERENCE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MORBIDITY; MORTALITY; MULTIDRUG RESISTANCE; NONHUMAN; PHAGOCYTOSIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE;

EID: 3242678614     PISSN: 0954139X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.revmedmi.0000131429.20976.8f     Document Type: Review

References (106)

1. Obaro SK. The new pneumooccal vaccine. Clin Microbiol Infect 2002; 8:623-633.
2. Bartlett JG. Respiratory tract infections. Philadelphia: Lippincott Williams and Wilkins; 2001.
3. Boulnois GJ. Pneumococcal proteins and the pathogenesis of disease caused by Streptococcus pneumoniae. J Gen Microbiol 1992; 138:249-259.
4. Tuomanen EI, Masure HR. Molecular and cellular biology of pneumococcal infection. In: Tomasz A, editor. Streptococcus pneumoniae. Molecular biology and mechanisms of disease. New York: Mary Ann Liebert, Inc.; 2000. pp. 295-308.
5. Watson DA, Musher DM. A brief history of the pneumococcus in biomedical research. Semin Respir Infect 1999; 14:198-208.
6. Butler JC. Epidemiology of pneumococcal serotypes and conjugate vaccine formulations. Microb Drug Resist 1997; 3: 125-129.
7. Dagan R, Yagupsky P, Goldbart A, Wasas A, Klugman KP. Increasing prevalence of penicillin-resistant pneumococcal infections in children in southern Israel: implications for future immunization policies. Pediatr Infect Dis J 1994; 13:782-786.
8. McGee L, Klugman KP, Tomasz A. Serotypes and clones of antibiotic-resistant pneumococci. In: Tomasz A, editor. Streptococcus pneumoniae. Molecular biology and mechanisms of disease. New York: Mary Ann Liebert, Inc.; 2000. pp. 375-379.
9. Tomasz A. A multinational workshop on drug-resistant pathogens of the respiratory tract: prevalence, risk factors and intervention strategies. Clin Microbiol Infect 1999; 5 (Suppl. 4): S1-S2.
10. Klein DL. Pneumococcal disease and the role of conjugate vaccines. Microb Drug Resist 1999; 5:147-157.
11. Fischer W. Pneumococcal lipoteichoic and teichoic acid. Microb Drug Resist 1997; 3:309-325.
12. Briles DE, Hollingshead SK, Swiatlo E, Brooks-Walter A, Szalai A, Virolainen A, et al. Pneumococcal proteins PspA and PspC: their potential for use as vaccines. In: Tomasz A, editor. Streptococcus pneumoniae. Molecular biology and mechanisms of disease. New York: Mary Ann Liebert, Inc.; 2000. pp. 253-260.
13. Hammerschmidt S, Bethe G, Remane PH, Chhatwal GS. Identification of pneumococcal surface protein a as a lactoferrin-binding protein of Streptococcus pneumoniae. Infect Immun 1999; 67:1683-1687.
14. Paton JC, Berry AM, Lock RA. Molecular analysis of putative pneumococcal virulence proteins. Microb Drug Resist 1997; 3:1-10.
15. Carlsen BD, Kawana M, Kawana C, Tomasz A, Giebink GS. Role of the bacterial-cell wall in middle-ear inflammation caused by Streptococcus pneumoniae. Infect Immun 1992; 60:2850-2854.
16. Geelen S, Bhattacharyya C, Tuomanen E. The cell wall mediates pneumococcal attachment to and cytopathology in human endothelial cells. Infect Immun 1993; 61:1538-1543.
17. Andrew PW, Mitchell TJ, Morgan PJ. Relationship of structure to function in pneumolysin [Review]. Microb Drug Resist 1997; 3:11-17.
18. Mitchell TJ, Andrew PW. Biological properties of pneumolysin. Microb Drug Resist 1997; 3:19-26.
19. López R, García E, García P, García JL. The pneumococcal cell wall degrading enzymes: a modular design to create new lysins? Microb Drug Resist 1997; 3:199-211.
20. Poulsen K, Reinholdt J, Kilian M. Characterization of the Streptococcus pneumoniae immunoglobulin A1 protease gene (iga) and its translation product. Infect Immun 1996; 64: 3957-3966.
21. Austrian R. The pneumococcus at the millennium: not down, not out. J Infect Dis 1999; 179 (Suppl. 2):338-341.
22. Klugman KP. Antibiotic selection of multiply resistant pneumococci. Clin Infect Dis 2001; 33:489-491.
23. Baquero F. Evolving resistance patterns of Streptococcus pneumoniae: a link with long-acting macrolide consumption? J Chemother 1999; 11 (Suppl. 1):35-41.
24. Seppälä H, Klaukka T, Vuopio-Varkila J, Muotiala A, Helenius H, Lager K, et al., and the Finnish Study Group of Antimicrobial Resistance. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. N Engl J Med 1997; 337:441-446.
25. Adam D. Global antibiotic resistance in Streptococcus pneumoniae. J Antimicrob Chemother 2002; 50 (Topic T1):1-5.
26. Balsalobre L, Ferrándiz MJ, Liñares J, Tubau F, de la Campa AG. Viridans group streptococci are donors in horizontal transfer of topoisomerase IV genes to Streptococcus pneumoniae. Antimicrob Agents Chemother 2003; 47:2072-2081.
27. Seppälä H, Haanpera M, Al-Juhaish M, Jarvinen H, Jalava J, Huovinen P. Antimicrobial susceptibility patterns and macrolide resistance genes of viridans group streptococci from normal flora. J Antimicrob Chemother 2003; 52:636-644.
28. Klugman KP. Pneumococcal resistance to antibiotics. Clin Microbiol Rev 1990; 3:171-196.
29. Barnes DM, Whittier S, Gilligan PH, Soares S, Tomasz A, Henderson FW. Transmission of multidrug-resistant serotype 23F Streptococcus pneumoniae in group day care: evidence suggesting capsular transformation of the resistant strain in vivo. J Infect Dis 1995; 171:890-896.
30. de Lencastre H, Tomasz A. From ecological reservoir to disease: the nasopharynx, day-care centres and drug-resistant clones of Streptococcus pneumoniae. J Antimicrob Chemother 2002; 50:75-81.
31. Sá-Leão, R, Tomasz A, Sanches IS, Nunes S, Alves CR, Avo AB, et al. Genetic diversity and clonal patterns among antibiotic-susceptible and -resistant Streptococcus pneumoniae colonizing children: day care centers as autonomous epidemiological units. J Clin Microbiol 2000; 38:4137-4144.
32. Tomasz A. The challenge of multiresistant Streptococcus pneumoniae: international initiatives in day-care centers and the use of molecular epidemiologic techniques. Clin Microbiol Infect 1999; 5 (Suppl. 4):S64-S68.
33. Amyes SGB. Magic bullets, lost horizons - the rise and fall of antibiotics. London: Taylor and Francis; 2001.
34. O'Brien TF. Emergence, spread, and environmental effect of antimicrobial resistance: how use of an antimicrobial anywhere can increase resistance to any antimicrobial anywhere else. Clin Infect Dis 2002; 34 (Suppl. 3):S78-S84.
35. Jacobs MR, Felmingham D, Appelbaum PC, Grüneberg RN, and The Alexander Project Group. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003; 52:229-246.
36. Felmingham D, Reinert RR, Jirakata Y, Rodloff A. Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and comparative in vitro activity of the ketolide, telithromycin. J Antimicrob Chemother 2002; 50 (Suppl. S1):25-37.
37. Blosser RS, Sahm DF, Thornsberry C, Jones ME. A current perspective of antimicrobial resistance among respiratory infections worldwide: results from the GLOBAL Surveillance. In: Program and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, USA, 14-17 September 2003, 133 [Abstract C2-1260].
38. EARSS Management Team, Schrijnemakers P (EARSS project coordinator). EARSS Annual Report 2001. Available at: http://www.earss.rivm.nl. Bilthoven, the Netherlands; July 2002.
39. Hoban DJ, Doern GV, Fluit AC, Roussel-Delvallez M, Jones RN. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella ctarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001; 32 (Suppl. 2):81-93.
40. Schmitz FJ, Perdikouli M, Beeck A, Verhoef J, Fluit AC. Molecular surveillance of macrolide, tetracycline and quinolone resistance mechanisms in 1191 clinical European Streptococcus pneumoniae isolates. Int J Antimicrob Agents 2001; 18:433-436.
41. Reinert RR, Appelbaum PC, Adler H, Al-Lahham A, Allerberger F, Allouch P, et al. Surveillance of antibiotic resistance among clinical isolates of Streptococcus pneumoniae in 2001-2002 in Europe - first results of the PNEUMOWORLD STUDY. In: Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, USA, 27-30 September 2002, 108 [Abstract C2-1623].
42. Bozdogan B, Appelbaum PC, Kelly LM, Hoellman DB, Tambic-Andrasevic A, Drukalska L, et al. Activity of telithromycin and seven other agents against 1034 pediatric Streptococcus pneumoniae isolates from ten central and eastern European centers. Clin Microbiol Infect 2003; 9:653-661.
43. Hoban DJ, Bouchillon SK, Karlowsky JA, Johnson JL, Butler DL, Miller LA, et al., and the Gemifloxacin Surveillance Study Research Group. A comparative in vitro surveillance study of gemifloxacin activities against 2,632 recent Streptococcus pneumoniae isolates from across Europe, North America, and South America. Antimicrob Agents Chemother 2000; 44:3008-3011.
44. Nagai K, Appelbaum PC, Davies TA, Kelly LM, Hoellman DB, Tambic-Andrasevic A, et al. Susceptibilities to telithromycin and six other agents and prevalence of macrolide resistance due to L4 ribosomal protein mutation among 992 pneumococci from 10 Central and Eastern European countries. Antimicrob Agents Chemother 2002; 46:371-377.
45. Charpentier E, Tuomanen E. Mechanisms of antibiotic resistance and tolerance in Streptococcus pneumoniae [Review]. Microbes Infect 2000; 2:1855-1864.
46. Nichol KA, Zhanel GG, Hoban DJ. Penicillin-binding protein 1A, 2B, and 2X alterations in Canadian isolets of penicillin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 2002; 46:3261-3264.
47. Hakenbeck R. Transformation in Streptococcus pneumoniae: mosaic genes and the regulation of competence. Res Microbiol 2000; 151:453-456.
48. Tomasz A. Antibiotic resistance in Streptococcus pneumoniae. Clin Infect Dis 1997; 24 (Suppl. 1):85-88.
49. Coffey TJ, Dowson CG, Daniels M, Spratt BG. Horizontal spread of an altered penicillin-binding protein 2B gene between Streptococcus pneumoniae and Streptococcus oralis. FEMS Microbiol Lett 1993; 110:335-339.
50. Hakenbeck R, König A, Kern I, van der Linden M, Keck W, Billot-Klein D, et al. Acquisition of five high-Mr penicillin-binding protein variants during transfer of high-level beta-lactam resistance from Streptococcus mitis to Streptococcus pneumoniae. J Bacteriol 1998; 180:1831-1840.
51. Filipe SR, Tomasz A. Inhibition of the expression of penicillin resistance in Streptococcus pneumoniae by inactivation of cell wall muropeptide branching genes. Proc Natl Acad Sci USA 2000; 97:4891-4896.
52. Smith AM, Klugman KP. Alterations in MurM, a cell wall muropeptide branching enzyme, increase high-level penicillin and cephalosporin resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 2001; 45:2393-2396.
53. Grebe T, Paik J, Hakenbeck R. A novel resistance mechanism against β-lactams in Streptococcus pneumoniae involves CpoA, a putative glycosyltransferase. J Bacteriol 1997; 179:3342-3349.
54. Guenzi E, Gasc A-M, Sicard MA, Hakenbeck R. A two-component signal-transducing system is involved in competence and penicillin susceptibility in laboratory mutants of Streptococcus pneumoniae. Mol Microbiol 1994; 12:505-515.
55. Klugman KP. The successful clone: the vector of dissemination of resistance in Streptococcus pneumoniae. J Antimicrob Chemother 2002; 50 (Suppl. S2):1-5.
56. Hansmann D, Bullen MM. A resistant pneumococcus. Lancet 1967; ii:264-265.
57. Hansmann D, Devitt L, Miles H, Riley I. Pneumococci relatively insensitive to penicillin in Australia and New Guinea. Med J Aust 1974; ii:353-356.
58. Cornaglia G, Fontana R. Epidemiological survey of bacterial resistance in upper respiratory tract infections in Italy. Int J Antimicrob Agents 2000; 16:259-262.
59. Dobay O, Rozgonyi F, Hajdú E, Nagy E, Knausz M, Amyes SGB. Antibiotic susceptibility and serotypes of Streptococcus pneumoniae isolates from Hungary. J Antimicrob Chemother 2003; 51:887-893.
60. Rozgonyi F, Kristóf K, Ghidán Á. Incidence and antibiotic resistance of streptococcal and enterococcal recent clinical strains from patients of the Semmelweis University hospitals. In: Abstracts of the 14th International Congress of the Hungarian Society for Microbiology including an ESCMID Symposium on 'Resurgence of Streptococcal Infections'. Balatonfured, Hungary, 9-11 October 2003.
61. Felmingham D, Grüneberg, RN, and the Alexander Project Group. The Alexander Project 1996-1997: Latest susceptibility data from this international study of bacterial pathogens from acquired lower respiratory tract infections. J Antimicrob Chemother 2000; 48:191-203,
62. Yu V, Chiou CC, Feldman C, Ortqvist A, Rello J, Morris AJ, et al., and the International Pneumococcal Study Group. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 2003; 37:230-237.
63. Ackermann G, Rodloff AC. Drugs of the 21st century: telithromycin (HMR 3647) - the first ketolide [Review]. J Antimicrob Chemother 2003; 51:497-511.
64. Leclercq R, Courvalin P. Resistance to macrolides and related antibiotics in Streptococcus pneumoniae [Minireview]. Antimicrob Agents Chemother 2002; 46:2727-2734.
65. Roberts MC, Sutcliffe J, Courvalin P, Jensen LB, Rood J, Seppälä H. Nomenclature for macrolide and macrolide-lincosamide- streptogramin B resistance determinants. Antimicrob Agents Chemother 1999; 43:2823-2830.
66. Farrell DJ, Morrissey L, Bakker S, Felmingham D. Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 1999-2000 study. J Antimicrob Chemother 2002; 50 (Suppl. S1):39-47.
67. Betriu C, Redondo M, Palau ML, Sanchez A, Gomez M, Culebras E. Comparative in vitro activities of linezolid, quinupristin-dalfopristin, moxifloxacin, and trovafloxacin against erythromycin-susceptible and -resistant streptococci. Antimicrob Agents Chemother 2000; 44:1838-1841.
68. Syrogiannopoulos GA, Grivea IN, Tait-Kamradt A, Katopodis GD, Beratis NG, Sutcliffe J, et al. Identification of an erm(A) erythromycin resistance methylase gene in Streptococcus pneumoniae isolated in Greece. Antimicrob Agents Chemother 2001; 45:342-344.
69. Seppälä H, Skurnik M, Soini H, Roberts MC, Huovinen P. A novel erythromycin resistance methylase gene (ermTR) in Streptococcus pyogenes. Antimicrob Agents Chemother 1998; 42:257-262.
70. Tait-Kamradt A, Davies TA, Appelbaum PC, Depardieu F, Courvalin P, Petitpas J, et al. Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America. Antimicrob Agents Chemother 2000; 44:3395-3401.
71. Sutcliffe J, Tait-Kamradt A, Wondrack L. Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. Antimicrob Agents Chemother 1996; 40:1817-1824.
72. Tait-Kamradt A, Clansy J, Cronan M, Dib-Hajj F, Wondrack L, Yuan W, et al. MefE is necessary for the erythromycin-resistant M phenotype in Streptococcus pneumoniae. Antimicrob Agents Chemother 1997; 41:2251-2255.
73. Del Grosso M, Ianelli F, Messina C, Santagati M, Petrosillo N, Stefani S, et al. Macrolide efflux genes mef(A) and mef(E) are carried by different genetic elements in Streptococcus pneumoniae. J Clin Microbiol 2002; 40:774-778.
74. McDougal LK, Tenover FC, Lee LN, Rasheed JK, Patterson JE, Jorgensen JH, et al. Detection of Tn917-like sequences within a Tn916-like conjugative transposon (Tn3872) in erythromycin-resistant isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 1998; 42:2312-2318.
75. Seral C, Castillo FJ, Rubio-Calvo MC, Fenoll A, Garcia C, Gomez-Lus R, et al. Distribution of resistance genes tet(M), aph3′-III, catpC194 and the integrase gene of Tn1545 in clinical Streptococcus pneumoniae harbouring erm(B) and mef(A) genes in Spain. J Antimicrob Chemother 2001; 47:863-866.
76. Santagati M, Ianelli F, Oggioni MR, Stefani S, Pozzi G. Characterization of a genetic element carrying the macrolide efflux gene mefA in Streptococcus pneumoniae. Antimicrob Agents Chemother 2000; 44:2585-2587.
77. Gay K, Stephens DS. Structure and dissemination of a chromosomal insertion element encoding macrolide efflux in Streptococcus pneumoniae. J Infect Dis 2001; 184:56-65.
78. Adrian PV, Mendrick C, Loebenberg D, McNicholas P, Shaw KJ, Klugman KP, et al. Evernimicin (SCH27899) inhibits a novel ribosome target site: analysis of 23S ribosomal DNA mutants. Antimicrob Agents Chemother 2000; 44:3101-3106.
79. Canu A, Malbruny B, Coquemont M, Davies TA, Appelbaum PC, Leclercq R. Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in Streptococcus pneumoniae. Antimicrob Agents Chemother 2002; 46:125-131.
80. Tait-Kamradt A, Davies T, Cronan M, Jacobs MR, Appelbaum PC, Sutcliffe J. Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage. Antimicrob Agents Chemother 2000; 44:2118-2125.
81. Jones RN, Farrell DJ, Morrissey I. Quinupristin-dalfopristin resistance in Streptococcus pneumoniae: novel L22 ribosomal protein mutation in two clinical isolates from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother 2003; 47:2696-2698.
82. Musher DM, Dowell ME, Shortridge VD, Flamm RK, Jorgensen JH, Le Magueres P, et al. Emergence of macrolide resistance during treatment of pneumococcal pneumonia. N Engl J Med 2002; 346:630-631.
83. Pihlajamäki M, Kataja J, Seppälä H, Elliot J, Leinonen M, Huovinen P, et al. Ribosomal mutations in Streptococcus pneumoniae clinical isolates. Antimicrob Agents Chemother 2002; 46:654-658.
84. Reinert RR, Wild A, Appelbaum PC, Lütticken R, Cil MY, Al-Lahham A. Ribosomal mutations conferring resistance to macrolides in Streptococcus pneumoniae clinical strains isolated in Germany. Antimicrob Agents Chemother 2003; 47:2319-2322.
85. Davies TA, Dewasse BE, Jacobs MR, Appelbaum PC. In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae. Antimicrob Agents Chemother 2000; 44:414-417.
86. Walsh F, Willcock J, Amyes S. High-level telithromycin resistance in laboratory-generated mutants of Streptococcus pneumoniae. J Antimicrob Chemother 2003; 52:345-353.
87. Tait-Kamradt A, Reinert RR, Al-Lahham A, Low DE, Sutcliffe J. High-level ketolide-resistant streptococci. In: Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, USA, 16-19 December 2001, 101 [Abstract C1-1813].
88. Weisblum B. Pneumococcus resistant to erythromycin and lincomycin. Lancet 1967; 1:843-844.
89. Ruiz J. Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection. J Antimicrob Chemother 2003; 51:1109-1117.
90. Read RC, Morrissey I, Ambler JE. Respiratory tract infections and fluoroquinolones. London: Science Press Ltd.; 2000.
91. Martínez-Martínez L, Pascual A, Jacoby GA. Quinolone resistance from a transferable plasmid. Lancet 1998; 351:797-799.
92. Canton R, Morosini M, Enright MC, Morrissey I. Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme. J Antimicrob Chemother 2003; 52:944-952.
93. Schmitz F-J, Perdikouli M, Beeck A, Verhoef J, Fluit AC. Resistance to trimethoprim-sulfamethoxazole and modifications in genes coding for dihydrofolate reductase and dihydropteroate synthase in European Streptococcus pneumoniae isolates. J Antimicrob Chemother 2001; 48:935-936.
94. Cybulska J, Jeljaszewic J, Lund E, Munksgaard A. Prevalence of types of Diplococcus pneumoniae and their susceptibility to 30 antibiotics. Chemotherapy 1970; 15:304-316.
95. Jacobs MR, Koornhof HJ, Robins-Browne RM, Stevenson CM, Vermaak ZA, Freiman I, et al. Emergence of multiply resistant pneumococci. N Engl J Med 1978; 299:735-740.
96. Novak R, Enriques B, Charpentier E, Normark S, Tuomanen E. Emergence of vancomycin tolerance in Streptococcus pneumoniae. Nature 1999; 399:590-593.
97. McCullers JA, English BK, Novak R. Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae from the cerebrospinal fluid of a patient who developed recrudescent meningitis. J Infect Dis 2000; 181:369-373.
98. McGee L, McDougal L, Zhou J, Spratt BG, Tenover FC, George R, et al. Nomenclature of major antimicrobial-resistant clones of Streptococcus pneumoniae defined by the Pneumococcal Molecular Epidemiology Network. J Clin Microbiol 2001; 39: 2565-2571.
99. Corso A, Severina EP, Petruk VF, Mauriz YR, Tomasz A. Molecular characterization of penicillin-resistant Streptococcus pneumoniae isolates causing respiratory tract disease in the United States. Microb Drug Resist 1998; 4:325-337.
100. Soares S, Kristinsson KG, Musser JM, Tomasz A. Evidence for the introduction of a multiresistant clone of serotype 6B Streptococcus pneumoniae from Spain to Iceland in the late 1980s. J Infect Dis 1993; 168:158-163.
101. Hall LMC, Whiley RA, Duke B, George RC, Efstratiou A. Genetic relatedness within and between serotypes of Streptococcus pneumoniae from the United Kingdom: analysis of multilocus enzyme electrophoresis, pulsed-field gel electrophoresis, and antimicrobial resistance patterns. J Clin Microbiol 1996; 34:853-859.
102. Coffey TJ, Dowson CG, Daniels M, Zhou J, Martin C, Spratt BG, et al. Horizontal transfer of multiple penicillin-binding protein genes, and capsular biosynthetic genes, in natural populations of Streptococcus pneumoniae. Mol Microbiol 1991; 5:2255-2260.
103. Coffey TJ, Enright MC, Daniels M, Morona JK, Morona R, Hryniewicz W, et al. Recombinational exchanges at the capsular polysaccharide biosynthetic locus lead to frequent serotype changes among natural isolates of Streptococcus pneumoniae. Mol Microbiol 1998; 27:73-83.
104. Pihlajamäki M, Kaijalainen T, Huovinen P, Jalava J, and the Finnish Study Group for Antimicrobial Resistance. Rapid increase in macrolide resistance among penicillin non-susceptible pneumococci in Finland, 1996-2000. J Antimicrob Chemother 2002; 49:785-792.
105. Marchese A, Tonoli E, Balistreri G, Debbia E, Schito GC. Antibiotic susceptibility patterns and serotypes of antibiotic resistant and/or invasive Streptococcus pneumoniae strains circulating in Italy. Microb Drug Resist 2000; 6:163-170.
106. Ip M, Lyon DJ, Yung RW, Chan C, Cheng AF. Macrolide resistance in Streptococcus pneumoniae in Hong Kong. Antimicrob Agents Chemother 2001; 45:1578-158.